ticagrelor and Colitis--Ulcerative

溃疡性结肠炎患者通常处于高凝状态且存在消化道出血，若同时合并急性心肌梗死则在药物及介入治疗方面存在诸多矛盾，通常预后较差，目前尚无公认的最佳治疗方案。该文报道1例重度活动性溃疡性结肠炎合并消化道出血的患者，院内发生急性下壁心肌梗死合并交界性心律及低血压，行急诊经皮冠状动脉介入治疗，于右冠状动脉病变行血栓抽吸及球囊扩张。术后予替格瑞洛90 mg（2次/d）抗血小板单药治疗，随访14个月无心绞痛发作，未出现便血加重。.

Topics: Acute Coronary Syndrome; Colitis, Ulcerative; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome

To evaluate the side effects of two antiplatelet agents - ticagrelor and eptifibatide - in mice with experimentally-induced inflammatory bowel disease.. This study was designed as a controlled, animal, drug safety investigation. C57Bl/6 mice were used to establish the ulcerative colitis model by exposure to dextran sulfate sodium (DSS), and divided into three experimental groups: eptifibatide-treated (150 µg/day intraperitoneally; n = 10), ticagrelol-treated (1 mg/day via gastric tube; n = 10), and DSS-control (plain drinking water; n = 10). An unmodeled non-DSS group served as the experimental control. Complete blood count was taken for all mice at baseline (day 0, treatment initiation) and after four days of treatment. On day 4, all animals were sacrificed for autopsy. The primary outcome measure was bleeding, and the secondary outcomes were change in platelet count, hemoglobin level, and hematocrit level.. Neither ticagrelor nor eptifibatide treatment produced a significant effect on DSS colitis mice for the safety parameters measured. Platelet count and hemoglobin and hematocrit levels were statistically similar between the three DSS groups and the non-DSS control group (P > 0.05). Autopsy found no evidence of recent bleeding in liver, spleen, central nervous system or serous cavities.. The antiplatelet agents ticagrelor and eptifibatide were safe in DSS colitis mice, suggesting their potential in humans suffering from ulcerative colitis, and supporting future safety studies.

Topics: Animals; Colitis, Ulcerative; Dextran Sulfate; Disease Models, Animal; Eptifibatide; Hematocrit; Hemoglobins; Mice; Mice, Inbred C57BL; Platelet Aggregation Inhibitors; Platelet Count; Ticagrelor

Inflammatory bowel diseases have been recognized as predisposing factors to atherosclerosis and thrombotic events, involving both the venous and the arterial circulatory systems. We report the case of a 70-year-old man who presented with ST elevation myocardial infarction during the active phase of ulcerative colitis (UC). Because of the ongoing hematochezia, after successful revascularization of the culprit vessel, the patient was medicated with Clopidogrel, in place of one of the more powerful new oral P2Y

Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Colitis, Ulcerative; Coronary Thrombosis; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticagrelor